Product Images Atorvastatin Calcium

This is a description for Atorvastatin Calcium Tablets, USP containing 1000 tablets, each tablet containing atorvastatin 10 mg. The usual dosage can be found in the package insert. It should be stored at 20° to 25°C, dispensed in tight containers, and further information can be obtained by calling the U.S. contact number provided. The product is manufactured for Quallent Pharmaceuticals Health LLC in the Cayman Islands by Annora Pharma Pvt. Ltd. based in Telangana, India. Please note the specific manufacturing license number provided.*

This is information for Atorvastatin Calcium tablets, a pharmaceutical product containing 20 mg of atorvastatin per film-coated tablet. This medication is prescription-only with 1000 tablets in a pack. The usual dosage information is provided in the package insert. The product should be stored at 20°C to 25°C and dispensed in tight containers. The manufacturer is Annora Pharma Pvt Ltd. located in Sangareddy, Telangana, India. For further inquiries, contact 1-877-605-7243.*

This is a description of Atorvastatin Calcium Tablets, USP. Each film-coated tablet contains 40 mg of atorvastatin. The package includes 1000 tablets and the usual dosage should be followed as per the package insert. It should be stored at 20° to 25°C and dispensed in tight containers. The manufacturer is Quallent Pharmaceuticals Health LLC, based in Grand Cayman, Cayman Islands, with the tablets produced by Annora Pharma Pvt. Ltd. from Telangana, India. For more information, the U.S. contact number is provided: 1-877-605-7243.*

This is a description for a pharmaceutical product containing Atorvastatin Calcium tablets, USP, with a dosage of 80 mg per film-coated tablet. The package size includes 1000 tablets. It is prescribed medication with a recommended storage temperature between 20°C to 25°C. The manufacturing details indicate it is produced in India for Quallent Pharmaceuticals Health LLC in Grand Cayman, Cayman Islands. For full prescribing information, one should refer to the package insert.*

This text provides information about a study or report labeled as HR063, with additional data like numbers and a description of the primary endpoint analysis over a four-year follow-up period. It seems to relate to health, research, or clinical trial outcomes.*